Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans

Sergej M Ostojic, Barbara Niess, Marko Stojanovic, Milos Obrenovic, Sergej M Ostojic, Barbara Niess, Marko Stojanovic, Milos Obrenovic

Abstract

Objectives: Guanidinoacetic acid (GAA) is a natural precursor of creatine, yet the potential use of GAA as a nutritional additive for restoring creatine availability in humans has been limited by unclear efficacy and safety after exogenous GAA administration. The present study evaluated the effects of orally administered GAA on serum and urinary GAA, creatine and creatinine concentration, and on the occurrence of adverse events in healthy humans.

Methods and results: Twenty-four healthy volunteers were randomized in a double-blind design to receive either GAA (2.4 grams daily) or placebo (PLA) by oral administration for 6 weeks.

Clinical trial registration: www.clinicaltrials.gov, identification number NCT01133899. Serum creatine and creatinine increased significantly from before to after administration in GAA-supplemented participants (P < 0.05). The proportion of participants who reported minor side effects was 58.3% in the GAA group and 45.5% in the placebo group (P = 0.68). A few participants experienced serum creatine levels above 70 µmol/L.

Conclusion: Exogenous GAA is metabolized to creatine, resulting in a significant increase of fasting serum creatine after intervention. GAA had an acceptable side-effects profile with a low incidence of biochemical abnormalities.

Keywords: Clinical markers.; Creatine synthesis; Creatinine.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists. None of the funding sources had any role in the design and conduct of the study. All authors reviewed the paper, and read and approved the final manuscript. Study concept and design: SMO. Acquisition of data: SMO, MS & MO. Analysis of the data: SMO. Interpretation of data: SMO & BN. Drafting of the manuscript: SMO & BN. Critical revision of the manuscript for important intellectual content: SMO & MO. Statistical analysis: SMO & MS.

References

    1. Walker JB. Creatine: biosynthesis, regulation, function. Adv Enzymol Relat Areas Mol Biol. 1979;50:177–242.
    1. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107–213.
    1. Van Pilsum JF. Evidence for a dual role of creatine in the regulation of kidney transamidinase activities in the rat. J Nutr. 1971;101:1085–92.
    1. McGuire DM, Grioss MD, Van Pilsum JF. et al. Repression of rat kidney L-arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. J Biol Chem. 1984;259:12034–8.
    1. Edison EE, Brosnan ME, Meyer C. et al. Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. Am J Physiol Renal Physiol. 2007;293:F1799–804.
    1. Snow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem. 2001;224:169–81.
    1. Brosnan JT, Brosnan ME. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr. 2007;27:241–61.
    1. Stead LM, Au KP, Jacobs RL. et al. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab. 2001;281:E1095–100.
    1. Fukada S, Setoue M, Morita T. et al. Dietary eritadenine suppresses guanidinoacetic acid-induced hyperhomocysteinemia in rats. J Nutr. 2006;136:2797–802.
    1. Zugno AI, Stefanello FM, Scherer EB. et al. Guanidinoacetate decreases antioxidant defenses and total protein sulfhydryl content in striatum of rats. Neurochem Res. 2008;33:1804–10.
    1. European Food Safety Authority. Safety and efficacy of guanidinoacetic acid as feed additive for chickens for fattening. EFSA J. 2009;988:1–30.
    1. Michiels J, Maertens L, Buyse J. et al. Supplementation of guanidinoacetic acid to broiler diets: effects on performance, carcass characteristics, meat quality, and energy metabolism. Poult Sci. 2012;91:402–12.
    1. Borsook ME, Borsook H. Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg. 1951;5:830–55.
    1. Graybiel A, Patterson CA. Use of betaine and glycocyamine in the treatment of patients with heart disease: preliminary report. Ann West Med Surg. 1951;5:.863–75.
    1. Higgins AR, Harper HA, Kline EF. et al. Effects of creatine precursors in arthritis; clinical and metabolic study of glycocyamine and betaine. Calif Med. 1952;77:14–8.
    1. Dixon HH, Dickel HA, Shanklin JG. et al. Therapy in anxiety states and anxiety complicated by depression. West J Surg Obstet Gynecol. 1954;62:338–41.
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
    1. Rawson ES, Stec MJ, Frederickson SJ. et al. Low-dose creatine supplementation enhances fatigue resistance in the absence of weight gain. Nutrition. 2011;27:451–5.
    1. Benzi G. Is there a rationale for the use of creatine either as nutritional supplementation or drug administration in humans participating in a sport? Pharmacol Res. 2000;41:255–64.
    1. GRAS Notice No.GRN000118. .
    1. American College of Sports Medicine, American Dietetic Association, Dietitians of Canada. Joint Position Statement: nutrition and athletic performance. Med Sci Sports Exerc. 2000;32:2130–45.
    1. Balsom PD, Söderlund K, Ekblom B. Creatine in humans with special reference to creatine supplementation. Sports Med. 1994;18:268–80.
    1. del Campo G, Gallego B, Berregi I, Casado JA. Creatinine, creatine and protein in cooked meat products. Food Chem. 1998;63:187–90.
    1. Pais P, Salmon CP, Knize MG, Felton JS. Formation of mutagenic/carcinogenic heterocyclic amines in dry-heated model systems, meats, and meat drippings. J Agric Food Chem. 1999;47:1098–108.
    1. Carducci C, Birarelli M, Leuzzi V. et al. Guanidinoacetate and creatine plus creatinine assessment in physiologic fluids: an effective diagnostic tool for the biochemical diagnosis of arginine:glycine amidinotransferase and guanidinoacetate methyltransferase deficiencies. Clin Chem. 2002;48:1772–8.
    1. Jaki T, Wolfsegger MJ, Ploner M. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods. Pharm Stat. 2009;8:12–24.
    1. Lemme A, Tossenberger J, Ringel J. Digestibility and availability of the creatine source guanidinoacetic acid in broilers. Poult Sci. 2007;86(Suppl 1):153.
    1. Mayhew DL, Mayhew JL, Ware JS. Effects of long-term creatine supplementation on liver and kidney functions in American college football players. Int J Sport Nutr Exerc Metabol. 2002;12:453–60.
    1. Heymsfield SB, Arteaga C, McManus C. et al. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983;37:478–94.
    1. Hultman E, Söderlund K, Timmons JA. et al. Muscle creatine loading in men. J Appl Physiol. 1996;81:232–7.
    1. Volek JS, Duncan ND, Mazzetti SA. et al. No effect of heavy resistance training and creatine supplementation on blood lipids. Int J Sport Nutr Exerc Metabol. 2000;10:144–56.
    1. Deldicque L, Décombaz J, Zbinden Foncea H. et al. Kinetics of creatine ingested as a food ingredient. Eur J Appl Physiol. 2008;102:133–43.
    1. Poortmans JR, Francaux M. Long-therm oral creatine supplementation does not impair renal function in healthy athletes. Med Sci Sports Exerc. 1999;31:1108–10.
    1. Mihic S, MacDonald JR, McKenzie S. et al. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med Sci Sports Exerc. 2000;32:291–6.
    1. Pline KA, Smith CL. The effect of creatine intake on renal function. Ann Pharmacother. 2005;39:1093–6.
    1. Gualano B, Ugrinowitsch C, Novaes RB. et al. Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial. Eur J Appl Physiol. 2008;103:33–40.
    1. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46.
    1. Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease process. Seminars Vasc Med. 2005;5:77–86.
    1. Ohuchi S, Matsumoto Y, Morita T. et al. High-casein diet suppresses guanidinoacetic acid-induced hyperhomocysteinemia and potentiates the hypohomocysteinemic effect of serine in rats. Biosci Biotechnol Biochem. 2008;72:3258–64.
    1. Setoue M, Ohuchi S, Morita T. et al. Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats. Biosci Biotechnol Biochem. 2008;72:1696–1703.
    1. Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19:227–33.
    1. Pilz S, Meinitzer A, Tomaschitz A. et al. Low homoarginine concentration is a novel risk factor for heart disease. Heart. 2011;97:1222–7.
    1. Meinitzer A, Drechsler C, Tomaschitz A. et al. Homoarginine: a new cardiovascular risk marker in hemodialysis patients. J Lab Med. 2011;35:153–9.
    1. Derave W, Marescau B, Vanden Eede E, Eijnde BO, De Deyn PP, Hespel P. Plasma guanidino compounds are altered by oral creatine supplementation in healthy humans. J Appl Physiol. 2004;97:852–857.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel